Why Is KRYSTAL BIOTECH INC (KRYS) Stock Down Today?
By the Top Tier Newswire AI Desk · August 3, 2026 at 12:25 PM ET · reviewed against 6 wire stories
KRYSTAL BIOTECH INC (KRYS) is down -12.00% in the latest session. Our newswire has captured 6 stories on KRYS across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
KRYS stock fell 12.00% to $300.17 on Friday, marking one of the largest single-day declines in recent months. The decline came despite Krystal Biotech reporting second-quarter earnings that beat estimates and posting a 24% year-over-year revenue increase. The stock slid after the company reported revenue of $119.22 million, which fell short of the $121.06 million forecast. The earnings beat was not enough to offset concerns over the revenue miss and broader market sentiment.
What Happened
Krystal Biotech reported GAAP earnings per share of $1.79, exceeding the $1.66 expected by analysts. However, the company’s revenue of $119.22 million missed estimates by $1.82 million. The shortfall, though modest in absolute terms, raised questions about the sustainability of its growth trajectory. VYJUVEK, the company’s lead product, continued to drive revenue with global sales of $119.2 million in the quarter. Despite this, the market reacted negatively to the revenue miss and the broader context of earnings volatility. The company also announced it would discontinue a clinical study for KB801 to advance the drug into a pivotal trial, a move that may have added uncertainty for investors.
What The Data Shows
The stock opened at $341.72 and quickly declined throughout the session, hitting a low of $300.00 before closing at $300.15. The volume of 0.4 million shares traded was in line with the 3-month average. Krystal Biotech has a market cap of $10.1 billion, a P/E ratio of 45.7, and a net margin of 53.9%. Revenue has grown by 25.1% in the trailing twelve months. The stock is currently trading within its 52-week range of $130.50 to $382.54. Recent insider transactions include four sales totaling $15.9 million over the past 90 days, with no insider purchases reported.
What To Watch
The company is scheduled to report further clinical readouts in the second half of 2026. Investors will also be watching for VYJUVEK launches in Spain and Italy later this year. Analysts from B of A Securities and TD Cowen have both maintained Buy ratings, with raised price targets of $396 and $403 respectively.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Krystal Biotech beat second-quarter earnings estimates but missed revenue forecasts as VYJUVEK sales continued to grow and the company expanded its commercial presence across Europe.
7d agoMarketChameleonBULLISH 73Earnings
Krystal Biotech’s Q2 2026: Robust VYJUVEK Momentum, Multiple Late-Stage Readouts Ahead, and Strong Financials
August 3, 2026
Krystal Biotech delivered $119.2 million in global VYJUVEK revenue in Q2 2026 and ended the quarter with $1.1 billion in cash. With several pivotal clinical readouts, international launches, and a growing pipeline in the next year, KRYS is aiming for a transition from a single-product leader to a multi-product genetic medicine company.
7d agoInvesting.com MarketsBEARISH 34General
Why is Krystal Biotech stock sliding today?
Why is Krystal Biotech stock sliding today?
7d agoSeeking AlphaBULLISH 56Earnings
Krystal Biotech GAAP EPS of $1.79 beats by $0.16, revenue of $119.22M misses by $1.82M
Krystal Biotech (KRYS) Q2 results: GAAP EPS beats, revenue up 24% Y/Y but misses; VYJUVEK sales and FY2026 expense guidance.
7d agoSEC 8-KNEUTRAL 50General
Krystal Biotech, Inc. (KRYS) files 8-K
Filed: 2026-08-03 AccNo: 0001711279-26-000058 Size: 587 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
7d agoBusiness InsiderBULLISH 63Earnings
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →